LEAP THERAPEUTICS, INC. Quarterly Operating Income (Loss) in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Leap Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2016 to Q3 2024.
  • Leap Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$17.9M, a 20.4% decline year-over-year.
  • Leap Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$68.8M, a 20.2% increase year-over-year.
  • Leap Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$87M, a 53.3% decline from 2022.
  • Leap Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$56.8M, a 37% decline from 2021.
  • Leap Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$41.4M, a 45.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$68.8M -$17.9M -$3.02M -20.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$65.7M -$21.3M -$6.59M -44.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$59.1M -$14.8M +$27.9M +65.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$87M -$14.8M -$877K -6.29% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$86.2M -$14.8M +$455K +2.98% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$86.6M -$14.7M +$2.24M +13.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$88.9M -$42.7M -$32.1M -302% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$56.8M -$13.9M -$3.46M -32.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$53.3M -$15.3M -$3.15M -25.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$50.2M -$16.9M -$7.27M -75.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$42.9M -$10.6M -$1.46M -15.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$41.4M -$10.5M -$3.33M -46.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 -$38.1M -$12.1M -$4.63M -61.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$33.5M -$9.63M -$2.13M -28.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$31.3M -$9.17M -$2.79M -43.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$28.5M -$7.15M +$1.12M +13.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$29.7M -$7.51M +$415K +5.24% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$30.1M -$7.5M +$965K +11.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$31M -$6.38M +$2.41M +27.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$33.5M -$8.27M +$699K +7.79% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$34.2M -$7.92M +$676K +7.86% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$34.8M -$8.46M -$1.62M -23.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$33.2M -$8.8M -$2.45M -38.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$30.8M -$8.97M -$2.43M -37% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$28.3M -$8.6M -$17K -0.2% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$28.3M -$6.84M +$179K +2.55% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$28.5M -$6.34M +$3.86M +37.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$32.4M -$6.55M +$1.39M +17.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 -$33.7M -$8.58M -$1.55M -22.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$32.2M -$7.02M +$178K +2.47% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$32.4M -$10.2M -$5.07M -98.5% Jan 1, 2017 Mar 31, 2017 10-Q/A 2018-08-08
Q4 2016 -$27.3M -$7.94M Oct 1, 2016 Dec 31, 2016 10-K 2018-02-23
Q3 2016 -$7.03M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$7.19M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 -$5.14M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.